share_log

Piper Sandler Initiates Coverage On Agios Pharmaceuticals With Overweight Rating, Announces Price Target of $41

Piper Sandler Initiates Coverage On Agios Pharmaceuticals With Overweight Rating, Announces Price Target of $41

派珀·桑德勒以增持评级开始对Agios Pharmicals进行报道,宣布目标股价为41美元
Benzinga Real-time News ·  2023/02/03 05:03

Piper Sandler analyst Christopher Raymond initiates coverage on Agios Pharmaceuticals (NASDAQ:AGIO) with a Overweight rating and announces Price Target of $41.

Piper Sandler分析师Christopher Raymond对Agios PharmPharmticals(纳斯达克:AGIO)发起增持评级,并宣布目标价为41美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发